Urovant Sciences Announces U.S. FDA Approval of GEMTESA
WEBIRVINE, Calif. & BASEL, Switzerland– (BUSINESS WIRE)– Urovant Sciences, a biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced the commercial launch of GEMTESA ® (vibegron) 75 mg tablets, a beta-3 (β3) adrenergic receptor agonist, for the treatment of overactive bladder...
Welcome to Urovant Sciences Medical Affairs
WEBUROVANT, UROVANT SCIENCES, and the UROVANT SCIENCES logo are trademarks of Urovant Sciences GmbH, registered in the U.S. and in other countries. All other trademarks are the property of their respective owners. © 2023 Urovant Sciences.
Urovant Sciences - LinkedIn
WEBUrovant Sciences is now Sumitomo Pharma America (SMPA), a science-based, technology-driven biopharmaceutical company focused on delivering therapeutic and scientific breakthroughs in areas of ...
Urovant, prepping Gemtesa for crowded overactive bladder field, pivots ...
WEBJan 22, 2021 · Urovant has been revving up to launch Gemtesa, its first approved med, with an overactive bladder awareness campaign, but now it's shifting into branded-campaign gear—and staff.
Innovative Treatments, Science and Technology | Sumitomo …
WEBWe drive innovative treatments, science, and technology to address patient needs in the critical areas of psychiatry & neurology, oncology, urology, women's health, rare disease, and cell & gene therapy. Learn More.
Urovant Sciences Announces U.S. FDA Approval of GEMTESA
WEBGEMTESA is the first new oral branded OAB medication approved by the U.S. FDA since 2012 and the first product approval for Urovant Sciences. U.S. commercial launch planned in late-Q1 2021. IRVINE, Calif. & BASEL, Switzerland– (BUSINESS WIRE)–Dec. 23, 2020– Urovant Sciences (Nasdaq: UROV) announced today that the U.S. Food and Drug ...
Sumitovant Biopharma Completes Acquisition of Urovant Sciences
WEBMar 29, 2021 · Urovant Sciences, a subsidiary of Sumitovant Biopharma Ltd., intends to develop novel treatments for additional urologic diseases. Learn more about us at www.urovant.com.
Sumitovant Enters into an Agreement for "Going ... - Sumitomo …
WEBNov 13, 2020 · Sumitomo Dainippon Pharma and Sumitovant will place Urovant a wholly owned subsidiary in order to provide optimal support for Urovant, which requires funding and other support for the launch in the U.S. of vibegron, whose New Drug Application has been submitted to the U.S. Food and Drug Administration (FDA), and to …
Urovant Sciences - Products, Competitors, Financials, Employees ...
WEBUrovant Sciences is a global biopharmaceutical company focusing on developing and commercializing therapies for urologic conditions. On March 23rd, 2021, Urovant Sciences was acquired by Sumitovant. Use the CB Insights Platform to …
Urovant Sciences® Presents New Data from EMPOWUR Study, …
WEBMay 15, 2022 · UROVANT, UROVANT SCIENCES, the UROVANT SCIENCES logo, GEMTESA, and the GEMTESA logo are trademarks of Urovant Sciences GmbH, registered in the U.S. and in other countries.
- Some results have been removed
Skip to content